{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:26:12Z","timestamp":1791257172500,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Persons on chronic hemodialysis have a significantly diminished humoral immune response to SARS-CoV-2 vaccines. Whether this translates to reduced vaccine effectiveness (VE) is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used the US Department of Veterans Affairs COVID-19 Shared Data Resource to identify all veterans who were tested for SARS-CoV-2 between 26 January and 31 August 2021. Using International Classification of Diseases, 10th edition, codes and attendance at a dialysis clinic\/center, we identified those who were on chronic hemodialysis. We used a test-negative, case-control design using a doubly robust logistic regression model to determine the VE of the BNT-162b2 (Pfizer) or mRNA-1273 (Moderna) vaccines in preventing confirmed SARS-CoV-2 infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 847\u00a0199 veterans tested for SARS-CoV-2 between 26 January and 31 August 2021, there were 6076 veterans on chronic hemodialysis. Among those, we identified 1270 cases (580 fully vaccinated) and 2959 controls (2120 fully vaccinated). The overall VE &amp;gt;14 days after the second dose in preventing documented infection was 68.2% (95% CI: 62.6\u201372.9%). VE was 68.9% (95% CI: 61.9\u201374.7%) for Pfizer BNT-162b2 and 66.7% (95% CI: 58.9\u201373.0%) for Moderna mRNA-1273 vaccine. There was no difference in VE by age (&amp;lt;70 vs &amp;gt;70 years), race, or sex. There were no events recorded in persons with a Charlson\u2019s comorbidity index score &amp;lt;2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VE of 2 doses of current mRNA vaccines in preventing SARS-CoV-2 infection in persons on chronic hemodialysis is lower than historic VE rates in the general population. Effects of additional doses in improving VE in this special population need further study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac118","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T20:12:38Z","timestamp":1644005558000},"page":"e617-e622","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-1826","authenticated-orcid":false,"given":"Adeel A","family":"Butt","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System , Pittsburgh, PA , USA"},{"name":"Departments of Medicine and Population Health Sciences, Weill Cornell Medicine , New York, NY , USA"},{"name":"Departments of Medicine and Population Health Sciences, Weill Cornell Medicine-Qatar , Doha , Qatar"},{"name":"Research in Quality Group, Hamad Medical Corporation , Doha , Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor B","family":"Talisa","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System , Pittsburgh, PA , USA"},{"name":"Research in Quality Group, Hamad Medical Corporation , Doha , Qatar"},{"name":"Department of Critical Care Medicine, CRISMA Center, University of Pittsburgh , Pittsburgh, PA , USA and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid S","family":"Shaikh","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad B","family":"Omer","sequence":"additional","affiliation":[{"name":"Yale Institute for Global Health, Yale School of Medicine , New Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian B","family":"Mayr","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System , Pittsburgh, PA , USA"},{"name":"Department of Critical Care Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA"},{"name":"Department of Critical Care Medicine, CRISMA Center, University of Pittsburgh , Pittsburgh, PA , USA and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2022082503040903400_CIT0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0002","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0003","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0004","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0005","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0006","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12882-021-02378-y","article-title":"Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody","volume":"22","author":"Ahmed","year":"2021","journal-title":"BMC Nephrol"},{"key":"2022082503040903400_CIT0007","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111653","article-title":"Epidemiology and outcomes of COVID-19 in home dialysis patients compared with in-center dialysis patients","volume":"1","author":"Hsu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2022082503040903400_CIT0008","doi-asserted-by":"publisher","DOI":"10.3390\/v13050756","article-title":"Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)","volume":"13","author":"Korth","year":"2021","journal-title":"Viruses"},{"key":"2022082503040903400_CIT0009","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/ndt\/gfab179","article-title":"Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls","volume":"36","author":"Simon","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2022082503040903400_CIT0010","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.kint.2021.04.006","article-title":"Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients","volume":"99","author":"Yanay","year":"2021","journal-title":"Kidney Int"},{"key":"2022082503040903400_CIT0011","volume-title":"COVID-19 vaccines for moderately to severely immunocompromised people","author":"Centers for Disease Control and Prevention.","year":"2021"},{"key":"2022082503040903400_CIT0012","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"2022082503040903400_CIT0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/EDE.0000000000001251","article-title":"A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic","volume":"31","author":"Vandenbroucke","year":"2020","journal-title":"Epidemiology"},{"key":"2022082503040903400_CIT0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/kww064","article-title":"Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness","volume":"184","author":"Sullivan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2022082503040903400_CIT0015","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab083","article-title":"Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses","volume":"28","author":"Abu-Raddad","year":"2021","journal-title":"J Travel Med"},{"key":"2022082503040903400_CIT0016","doi-asserted-by":"publisher","DOI":"10.1172\/jci153662","article-title":"SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women","volume":"131","author":"Butt","year":"2021","journal-title":"J Clin Invest"},{"key":"2022082503040903400_CIT0017","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.7326\/M21-1577","article-title":"SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting","volume":"174","author":"Butt","year":"2021","journal-title":"Ann Intern Med"},{"key":"2022082503040903400_CIT0018","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0019","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1541-0420.2005.00377.x","article-title":"Doubly robust estimation in missing data and causal inference models","volume":"61","author":"Bang","year":"2005","journal-title":"Biometrics"},{"key":"2022082503040903400_CIT0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2022082503040903400_CIT0021","volume-title":"Toolkit for weighting and analysis of nonequivalent groups: a guide to the twang package","author":"Ridgeway","year":"2021"},{"key":"2022082503040903400_CIT0022","first-page":"99","article-title":"Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy","volume":"66","author":"Hightower","year":"1988","journal-title":"Bull World Health Organ"},{"key":"2022082503040903400_CIT0023","doi-asserted-by":"crossref","first-page":"Article 13","DOI":"10.2202\/1557-4679.1146","article-title":"Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses","volume":"5","author":"Austin","year":"2009","journal-title":"Int J Biostat"},{"key":"2022082503040903400_CIT0024","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"2022082503040903400_CIT0025","author":"Centers for Disease Control and Prevenion.","year":"2021"},{"key":"2022082503040903400_CIT0026","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0027","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"2022082503040903400_CIT0028","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2115624","article-title":"BNT162b2 vaccine booster and mortality due to Covid-19","volume":"385","author":"Arbel","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac118\/42974877\/ciac118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e617\/45514163\/ciac118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e617\/45514163\/ciac118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T03:07:12Z","timestamp":1661396832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/1\/e617\/6525466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac118","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,2,9]]}}}